BIOMAT Database Logo BIOMAT Database Logo

[Pilot combination phase II study of mitomycin C plus cisplatin for non-small cell lung cancer]. 1989

E Shimizu, and T Kamei, and K Kimura, and J Mukai, and Y Nakamura, and E Kunishige, and K Fukuta, and K Tani, and S Sone, and T Ogura
3rd Dept. of Internal Medicine, Tokushima University School of Medicine.

Fifteen patients (six patients with adenocarcinoma, seven patients with squamous cell carcinoma, and two patients with large cell carcinoma) with advanced non-small cell lung cancer (NSCLC) were evaluable for mitomycin C (MMC; 8 mg/m2 day 1, 8, every 3-4 weeks) plus cisplatin (CDDP; 80 mg/m2 day 1, every 3-4 weeks). Ten patients had had prior chemotherapy. Among 15 evaluable patients, no patient achieved complete response, and two patients showed partial response. The response rate of MMC plus CDDP against NSCLC was 13.3%. Toxic effects included anorexia (80%), nausea and vomiting (67%), leukopenia (53%), anemia (47%), nephrotoxicity (47%), thrombopenia (27%), liver injury (27%), and fever (7%). These toxic effects were reversible and manageable. The combination of MMC and CDDP appears to be valuable regimen against advanced NSCLC.

UI MeSH Term Description Entries
D007564 Japan A country in eastern Asia, island chain between the North Pacific Ocean and the Sea of Japan, east of the Korean Peninsula. The capital is Tokyo. Bonin Islands
D007970 Leukopenia A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000). Leukocytopenia,Leukocytopenias,Leukopenias
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008937 Mitomycins A group of methylazirinopyrroloindolediones obtained from certain Streptomyces strains. They are very toxic antibiotics used as ANTINEOPLASTIC AGENTS in some solid tumors. PORFIROMYCIN and MITOMYCIN are the most useful members of the group.
D009325 Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
D010865 Pilot Projects Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work. Pilot Studies,Pilot Study,Pilot Project,Project, Pilot,Projects, Pilot,Studies, Pilot,Study, Pilot
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D002289 Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. Carcinoma, Non-Small Cell Lung,Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,Nonsmall Cell Lung Cancer,Carcinoma, Non Small Cell Lung,Carcinomas, Non-Small-Cell Lung,Lung Carcinoma, Non-Small-Cell,Lung Carcinomas, Non-Small-Cell,Non Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinomas

Related Publications

E Shimizu, and T Kamei, and K Kimura, and J Mukai, and Y Nakamura, and E Kunishige, and K Fukuta, and K Tani, and S Sone, and T Ogura
Mitomycin C, vindesine, and cisplatin in advanced non-small-cell lung cancer. A phase II study.
February 1992, American journal of clinical oncology,
E Shimizu, and T Kamei, and K Kimura, and J Mukai, and Y Nakamura, and E Kunishige, and K Fukuta, and K Tani, and S Sone, and T Ogura
A phase II study of vinorelbine, mitomycin C and cisplatin chemotherapy for advanced non-small cell lung cancer.
December 2002, The Korean journal of internal medicine,
E Shimizu, and T Kamei, and K Kimura, and J Mukai, and Y Nakamura, and E Kunishige, and K Fukuta, and K Tani, and S Sone, and T Ogura
A phase II study of mitomycin C, etoposide, and cisplatin in advanced non-small cell lung cancer.
January 2000, Cancer investigation,
E Shimizu, and T Kamei, and K Kimura, and J Mukai, and Y Nakamura, and E Kunishige, and K Fukuta, and K Tani, and S Sone, and T Ogura
Phase II evaluation of a combination of mitomycin C, vincristine, and cisplatin in advanced non-small cell lung cancer.
January 1986, Cancer,
E Shimizu, and T Kamei, and K Kimura, and J Mukai, and Y Nakamura, and E Kunishige, and K Fukuta, and K Tani, and S Sone, and T Ogura
Phase I study of cisplatin and docetaxel plus mitomycin C in patients with metastatic non-small cell lung cancer.
November 1999, Japanese journal of clinical oncology,
E Shimizu, and T Kamei, and K Kimura, and J Mukai, and Y Nakamura, and E Kunishige, and K Fukuta, and K Tani, and S Sone, and T Ogura
A phase III randomized trial of cisplatin plus vindesine versus cisplatin plus vindesine plus mitomycin C versus cisplatin plus vindesine plus ifosfamide for advanced non-small-cell lung cancer.
March 1996, Respirology (Carlton, Vic.),
E Shimizu, and T Kamei, and K Kimura, and J Mukai, and Y Nakamura, and E Kunishige, and K Fukuta, and K Tani, and S Sone, and T Ogura
A pilot study of mitomycin, ifosfamide and cisplatin as outpatient combination chemotherapy for advanced non-small cell lung cancer.
December 1991, Tumori,
E Shimizu, and T Kamei, and K Kimura, and J Mukai, and Y Nakamura, and E Kunishige, and K Fukuta, and K Tani, and S Sone, and T Ogura
Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study.
January 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
E Shimizu, and T Kamei, and K Kimura, and J Mukai, and Y Nakamura, and E Kunishige, and K Fukuta, and K Tani, and S Sone, and T Ogura
Cisplatin, vindesine, mitomycin-C and 13-cis retinoic acid in the treatment of advanced non small cell lung cancer. A phase II pilot study.
January 2000, Anticancer research,
E Shimizu, and T Kamei, and K Kimura, and J Mukai, and Y Nakamura, and E Kunishige, and K Fukuta, and K Tani, and S Sone, and T Ogura
Combination chemotherapy with cisplatin, vindesine and mitomycin-C for advanced, inoperable non-small-cell lung cancer.
May 1992, The Medical journal of Australia,
Copied contents to your clipboard!